Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies

Journal of General Virology

Volumn 95, Issue PART 8, 2014, Pages 1816-1826

  Yoshimura, Kazuhisa ^a,b   Harada, Shigeyoshi ^a,b   Boonchawalit, Samatchaya ^a,b   Kawanami, Yoko ^b   Matsushita, Shuzo ^b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MARAVIROC; NEUTRALIZING ANTIBODY;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; BLOOD AUTOTRANSFUSION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; IC 50; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DATA BANK; PROTEIN EXPRESSION; VIRUS CULTURE; WST-8 ASSAY;

ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA; SERIAL PASSAGE; TRIAZOLES;

EID: 84904440378     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.062885-0     Document Type: Article

References (47)

1. Anastassopoulou, C. G., Ketas, T. J., Klasse, P. J. & Moore, J. P. (2009). Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A 106, 5318-5323.
2. Berger, E. A., Murphy, P. M. & Farber, J. M. (1999). Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17, 657-700.
3. Berro, R., Sanders, R. W., Lu, M., Klasse, P. J. & Moore, J. P. (2009). Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog 5, e1000548.
4. Brelot, A., Heveker, N., Adema, K., Hosie, M. J., Willett, B. & Alizon, M. (1999). Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 73, 2576-2586.
5. Cormier, E. G. & Dragic, T. (2002). The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 76, 8953-8957.
6. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C. & other authors (2005). Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broadspectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49, 4721-4732.
7. Dragic, T., Trkola, A., Thompson, D. A., Cormier, E. G., Kajumo, F. A., Maxwell, E., Lin, S. W., Ying, W., Smith, S. O. & other authors (2000). A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A 97, 5639-5644.
8. Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., Koyanagi, S., Shiosaki, K., Higuchi, H. & other authors (2006). Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces crossneutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 80, 5552-5562.
9. Farzan, M., Mirzabekov, T., Kolchinsky, P., Wyatt, R., Cayabyab, M., Gerard, N. P., Gerard, C., Sodroski, J. & Choe, H. (1999). Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96, 667-676.
10. Fätkenheuer, G., Nelson, M., Lazzarin, A., Konourina, I., Hoepelman, A. I., Lampiris, H., Hirschel, B., Tebas, P., Raffi, F. & other authors (2008). Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359, 1442-1455.
11. Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A. & other authors (2008). Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359, 1429-1441.
12. Guttman, M., Kahn, M., Garcia, N. K., Hu, S. L. & Lee, K. K. (2012). Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120. J Virol 86, 8750-8764.
13. Harada, S., Yoshimura, K., Yamaguchi, A., Boonchawalit, S., Yusa, K. & Matsushita, S. (2013). Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro. J Gen Virol 94, 933-943.
14. Hatada, M., Yoshimura, K., Harada, S., Kawanami, Y., Shibata, J. & Matsushita, S. (2010). Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J Gen Virol 91, 1335-1345.
15. Henrich, T. J., Tsibris, A. M., Lewine, N. R., Konstantinidis, I., Leopold, K. E., Sagar, M. & Kuritzkes, D. R. (2010). Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate. J Acquir Immune Defic Syndr 55, 420-427.
16. Huang, C. C., Tang, M., Zhang, M. Y., Majeed, S., Montabana, E., Stanfield, R. L., Dimitrov, D. S., Korber, B., Sodroski, J. & other authors (2005). Structure of a V3-containing HIV-1 gp120 core. Science 310, 1025-1028.
17. Kessler, J. A., II, McKenna, P. M., Emini, E. A., Chan, C. P., Patel, M. D., Gupta, S. K., Mark, G. E., III, Barbas, C. F., III, Burton, D. R. & Conley, A. J. (1997). Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 13, 575-582.
18. Kimura, T., Yoshimura, K., Nishihara, K., Maeda, Y., Matsumi, S., Koito, A. & Matsushita, S. (2002). Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy. J Infect Dis 185, 53-60.
19. Kuhmann, S. E., Pugach, P., Kunstman, K. J., Taylor, J., Stanfield, R. L., Snyder, A., Strizki, J. M., Riley, J., Baroudy, B. M. & other authors (2004). Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 78, 2790-2807.
20. Landovitz, R. J., Angel, J. B., Hoffmann, C., Horst, H., Opravil, M., Long, J., Greaves, W. & Fätkenheuer, G. (2008). Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 198, 1113-1122.
21. + T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 69, 3712-3720.
22. Lyumkis, D., Julien, J. P., de Val, N., Cupo, A., Potter, C. S., Klasse, P. J., Burton, D. R., Sanders, R. W., Moore, J. P. & other authors (2013). Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484-1490.
23. Maeda, K., Yoshimura, K., Shibayama, S., Habashita, H., Tada, H., Sagawa, K., Miyakawa, T., Aoki, M., Fukushima, D. & Mitsuya, H. (2001). Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 276, 35194-35200.
24. Maeda, K., Das, D., Ogata-Aoki, H., Nakata, H., Miyakawa, T., Tojo, Y., Norman, R., Takaoka, Y., Ding, J. & other authors (2006). Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281, 12688-12698.
25. Maeda, K., Das, D., Yin, P. D., Tsuchiya, K., Ogata-Aoki, H., Nakata, H., Norman, R. B., Hackney, L. A., Takaoka, Y. & Mitsuya, H. (2008a). Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition. J Mol Biol 381, 956-974.
26. Maeda, Y., Yusa, K. & Harada, S. (2008b). Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120. Antiviral Res 77, 128-135.
27. Marozsan, A. J., Kuhmann, S. E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B. M., Strizki, J. & Moore, J. P. (2005). Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338, 182-199.
28. Ogert, R. A., Wojcik, L., Buontempo, C., Ba, L., Buontempo, P., Ralston, R., Strizki, J. & Howe, J. A. (2008). Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373, 387-399.
29. Ogert, R. A., Ba, L., Hou, Y., Buontempo, C., Qiu, P., Duca, J., Murgolo, N., Buontempo, P., Ralston, R. & Howe, J. A. (2009). Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc. J Virol 83, 12151-12163.
30. Ogert, R. A., Hou, Y., Ba, L., Wojcik, L., Qiu, P., Murgolo, N., Duca, J., Dunkle, L. M., Ralston, R. & Howe, J. A. (2010). Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 400, 145-155.
31. Pantophlet, R. & Burton, D. R. (2006). GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24, 739-769.
32. Pugach, P., Marozsan, A. J., Ketas, T. J., Landes, E. L., Moore, J. P. & Kuhmann, S. E. (2007). HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361, 212-228.
33. Ratcliff, A. N., Shi, W. & Arts, E. J. (2013). HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120. J Virol 87, 923-934.
34. Roche, M., Jakobsen, M. R., Ellett, A., Salimiseyedabad, H., Jubb, B., Westby, M., Lee, B., Lewin, S. R., Churchill, M. J. & Gorry, P. R. (2011a). HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology 8, 89.
35. Roche, M., Jakobsen, M. R., Sterjovski, J., Ellett, A., Posta, F., Lee, B., Jubb, B., Westby, M., Lewin, S. R. & other authors (2011b). HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism. J Virol 85, 4330-4342.
36. Shibata, J., Yoshimura, K., Honda, A., Koito, A., Murakami, T. & Matsushita, S. (2007). Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. J Virol 81, 3757-3768.
37. Shirasaka, T., Kavlick, M. F., Ueno, T., Gao, W. Y., Kojima, E., Alcaide, M. L., Chokekijchai, S., Roy, B. M., Arnold, E. & Yarchoan, R. (1995). Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A 92, 2398-2402.
38. Tilton, J. C., Wilen, C. B., Didigu, C. A., Sinha, R., Harrison, J. E., Agrawal-Gamse, C., Henning, E. A., Bushman, F. D., Martin, J. N. & other authors (2010). A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both Nterminal and extracellular loop domains of drug-bound CCR5. J Virol 84, 10863-10876.
39. Tsamis, F., Gavrilov, S., Kajumo, F., Seibert, C., Kuhmann, S., Ketas, T., Trkola, A., Palani, A., Clader, J. W. & other authors (2003). Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 77, 5201-5208.
40. Tsibris, A. M., Sagar, M., Gulick, R. M., Su, Z., Hughes, M., Greaves, W., Subramanian, M., Flexner, C., Giguel, F. & other authors (2008). In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 82, 8210-8214.
41. Westby, M., Lewis, M., Whitcomb, J., Youle, M., Pozniak, A. L., James, I. T., Jenkins, T. M., Perros, M. & van der Ryst, E. (2006). Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80, 4909-4920.
42. Westby, M., Smith-Burchnell, C., Mori, J., Lewis, M., Mosley, M., Stockdale, M., Dorr, P., Ciaramella, G. & Perros, M. (2007). Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81, 2359-2371.
43. Wyatt, R. & Sodroski, J. (1998). The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888.
44. Yoshimura, K., Shibata, J., Kimura, T., Honda, A., Maeda, Y., Koito, A., Murakami, T., Mitsuya, H. & Matsushita, S. (2006). Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 20, 2065-2073.
45. Yoshimura, K., Harada, S., Shibata, J., Hatada, M., Yamada, Y., Ochiai, C., Tamamura, H. & Matsushita, S. (2010). Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 84, 7558-7568.
46. Yuan, Y., Maeda, Y., Terasawa, H., Monde, K., Harada, S. & Yusa, K. (2011). A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc. Virology 413, 293-299.
47. Yusa, K., Maeda, Y., Fujioka, A., Monde, K. & Harada, S. (2005). Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem 280, 30083-30090.